Prasugrel, a third generation thienopyridine and potent platelet inhibitor

Curr Opin Investig Drugs. 2008 Mar;9(3):324-36.

Abstract

Eli Lilly & Co and Daiichi Sankyo Co Ltd are developing prasugrel, a third generation thienopyridine derivative. Prasugrel is in phase III clinical trials in Western Europe and Japan, and is awaiting regulatory approval in the US for the treatment of thromboembolism in patients with ischemic strokes or acute coronary syndromes. The companies were expected to launch the drug in the US by the end of 2008.

Publication types

  • Review

MeSH terms

  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Humans
  • Patents as Topic
  • Piperazines / adverse effects
  • Piperazines / chemical synthesis
  • Piperazines / pharmacokinetics
  • Piperazines / pharmacology
  • Piperazines / therapeutic use*
  • Platelet Aggregation Inhibitors / adverse effects
  • Platelet Aggregation Inhibitors / chemical synthesis
  • Platelet Aggregation Inhibitors / pharmacokinetics
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Prasugrel Hydrochloride
  • Structure-Activity Relationship
  • Thiophenes / adverse effects
  • Thiophenes / chemical synthesis
  • Thiophenes / pharmacokinetics
  • Thiophenes / pharmacology
  • Thiophenes / therapeutic use*
  • Thromboembolism / drug therapy*

Substances

  • Piperazines
  • Platelet Aggregation Inhibitors
  • Thiophenes
  • Prasugrel Hydrochloride